# Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

> **NCT01919619** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 41 (actual)

## Conditions studied

- B-Cell Non-Hodgkin Lymphoma
- Hematopoietic and Lymphoid Cell Neoplasm
- Leukemia
- Lymphoma
- Plasma Cell Myeloma
- T-Cell Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01919619
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-04
- **Primary completion:** 2024-05-03
- **Final completion:** 2024-05-03
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2024-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01919619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01919619, "Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01919619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*